{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:04:34Z","timestamp":1781273074155,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022558","name":"Deutsches Rheuma-Forschungszentrum, Leibniz-Gemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J1-4417"],"award-info":[{"award-number":["J1-4417"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["BI-DE\/23-24-011"],"award-info":[{"award-number":["BI-DE\/23-24-011"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["BI-US\/22-24-053"],"award-info":[{"award-number":["BI-US\/22-24-053"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118822","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:12:07Z","timestamp":1775315527000},"page":"118822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel pyrimidine and quinazoline-based small-molecule Toll-like receptor 8 antagonists"],"prefix":"10.1016","volume":"311","author":[{"given":"Troy","family":"Matziol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerij","family":"Talagayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Stra\u0161ek Benedik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Lauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"von Kempis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tja\u0161a","family":"Slokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Kulitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Weindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Wolber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-3450","authenticated-orcid":false,"given":"Matej","family":"Sova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118822_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118822_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118822_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/pr.114.010090","article-title":"Toll-like receptors in the vascular system: sensing the dangers within","volume":"68","author":"Goulopoulou","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2026.118822_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-\u03baB by toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118822_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620972","article-title":"Cell surface expression of endosomal toll-like receptors\u2014A necessity or a superfluous duplication?","volume":"11","author":"Mielcarska","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00291","article-title":"UNC93B1 mediates differential trafficking of endosomal TLRs","volume":"2","author":"Lee","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118822_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1259989","article-title":"Surface toll-like receptor 9 on immune cells and its immunomodulatory effect","volume":"14","author":"Kou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib9","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1038\/ncomms7119","article-title":"Targeting cell surface TLR7 for therapeutic intervention in autoimmune diseases","volume":"6","author":"Kanno","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118822_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941931","article-title":"Nucleic acid sensing by toll-like receptors in the endosomal compartment","volume":"13","author":"Miyake","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/ITT.S89795","article-title":"Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments","volume":"5","author":"Duffy","year":"2016","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.118822_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.00508","article-title":"Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejmech.2026.118822_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102482","article-title":"The path ahead for understanding toll-like receptor-driven systemic autoimmunity","volume":"91","author":"Hamerman","year":"2024","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/vim.2023.0077","article-title":"Toll-like receptors 7\/8: a paradigm for the manipulation of immunologic reactions for immunotherapy","volume":"36","author":"Li","year":"2023","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41584-024-01147-z","article-title":"UNC93B1 variants promote SLE via TLR activation","volume":"20","author":"Webster","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.118822_bib16","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.4049\/jimmunol.181.11.8002","article-title":"Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures","volume":"181","author":"Sacre","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/exd.12974","article-title":"Increased expression of toll-like receptors 3, 7, 8 and 9 in peripheral blood mononuclear cells in patients with psoriasis","volume":"25","author":"Kim","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejmech.2026.118822_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.118822_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104495","article-title":"Structure-guided approaches to modulate endosomal toll-like receptors TLR7, TLR8 and TLR9: advances, challenges and therapeutic promise","volume":"30","author":"Matziol","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118822_bib20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/molecules28020634","article-title":"Recent advances on small-molecule antagonists targeting TLR7","volume":"28","author":"Zheng","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118822_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118063","article-title":"Structure-based rational design of TLR7\/8 antagonists through agonist scaffold reengineering for psoriasis therapy","volume":"299","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113809","article-title":"Further hit optimization of 6-(trifluoromethyl)pyrimidin-2-amine based TLR8 modulators: synthesis, biological evaluation and structure\u2013activity relationships","volume":"225","author":"Dol\u0161ak","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/IM9.0000000000000119","article-title":"A biological perspective of TLR8 signaling in host defense and inflammation","volume":"5","author":"Bian","year":"2023","journal-title":"Infect. Microbes Dis."},{"key":"10.1016\/j.ejmech.2026.118822_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112238","article-title":"Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes","volume":"193","author":"Patinote","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nchembio.2518","article-title":"Small-molecule inhibition of TLR8 through stabilization of its resting state","volume":"14","author":"Zhang","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118822_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.molimm.2009.11.003","article-title":"A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition","volume":"47","author":"Liu","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejmech.2026.118822_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ecp.11.5","article-title":"The pharmacokinetics of toll-like receptor agonists and the impact on the immune system","volume":"4","author":"Engel","year":"2011","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118822_bib28","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.chembiol.2018.07.004","article-title":"Small-molecule TLR8 antagonists via structure-based rational design","volume":"25","author":"Hu","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118822_bib29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1126\/science.1229159","article-title":"Structural reorganization of the toll-like receptor 8 dimer induced by agonistic ligands","volume":"339","author":"Tanji","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118822_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128101","article-title":"Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): nucleic acid sensing antagonists and inhibitors","volume":"44","author":"Wang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118822_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.120.000275","article-title":"Discovery of M5049: a novel selective toll-like receptor 7\/8 inhibitor for treatment of autoimmunity","volume":"376","author":"Vlach","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118822_bib32","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/cpt.3216","article-title":"Asia-inclusive global development of enpatoran: results of an ethno-bridging study, intrinsic\/extrinsic factor assessments and disease trajectory modeling to inform design of a phase II multiregional clinical trial","volume":"115","author":"Klopp-Schulze","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118822_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.842","article-title":"Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8","volume":"9","author":"Port","year":"2021","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.ejmech.2026.118822_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001705","article-title":"Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7\/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study","volume":"12","author":"Witte","year":"2025","journal-title":"Lupus Sci. Med"},{"key":"10.1016\/j.ejmech.2026.118822_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70059","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of afimetoran, a toll-like receptor 7 and 8 inhibitor, in patients with cutaneous lupus erythematosus: a phase 1b randomized, double-blind, placebo-controlled study","volume":"7","author":"Hosein","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ejmech.2026.118822_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpdd.1176","article-title":"First-in-Human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of E6742, a dual antagonist of toll-like receptors 7 and 8, in healthy volunteers","volume":"12","author":"Yamakawa","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2026.118822_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175962","article-title":"A novel Toll-like receptor 7\/8\u2013specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus","volume":"957","author":"Ishizaka","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118822_bib38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acsmedchemlett.3c00136","article-title":"Discovery of the TLR7\/8 antagonist MHV370 for treatment of systemic autoimmune diseases","volume":"14","author":"Alper","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118822_bib39","article-title":"Preclinical characterization of the Toll-like receptor 7\/8 antagonist MHV370 for lupus therapy","volume":"4","author":"Hawtin","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2026.118822_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13318-023-00847-3","article-title":"First-in-Human study of the safety, pharmacokinetics, and pharmacodynamics of MHV370, a dual inhibitor of toll-like receptors 7 and 8, in healthy adults","volume":"48","author":"Shisha","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.118822_bib41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1021\/acsmedchemlett.2c00049","article-title":"Identification of 2-Pyridinylindole-Based dual antagonists of Toll-like receptors 7 and 8 (TLR7\/8)","volume":"13","author":"Sreekantha","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118822_bib42","doi-asserted-by":"crossref","first-page":"14537","DOI":"10.1021\/acs.jmedchem.5c00656","article-title":"Discovery of KBD4466, a selective TLR 7\/8 inhibitor, for the treatment of autoimmune diseases","volume":"68","author":"Yuan","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib43","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s12276-025-01526-w","article-title":"Discovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases","volume":"57","author":"Jeong","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118822_bib44","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1021\/acs.jmedchem.9b02128","article-title":"Rationally designed small-molecule inhibitors targeting an unconventional pocket on the TLR8 protein\u2013protein interface","volume":"63","author":"Jiang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib45","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.4c03148","article-title":"Discovery of novel isoxazole-based small-molecule toll-like receptor 8 antagonists","volume":"68","author":"Matziol","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib46","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/17460441.2021.1898369","article-title":"Recent trends in the development of Toll-like receptor 7\/8-targeting therapeutics","volume":"16","author":"Huang","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118822_bib47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ejmech.2019.06.084","article-title":"Identification and characterization of a novel chemotype for human TLR8 inhibitors","volume":"179","author":"\u0160ribar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1039\/C9MD00396G","article-title":"Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds","volume":"11","author":"Lazzara","year":"2019","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/tx015574b","article-title":"Biotransformation reactions of five-membered aromatic heterocyclic rings","volume":"15","author":"Dalvie","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118822_bib50","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jhet.4593","article-title":"An insight on medicinal attributes of pyrimidine scaffold: an updated review","volume":"60","author":"Vyas","year":"2023","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib51","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/cbdd.14001","article-title":"Pyrimidine: an elite heterocyclic leitmotif in drug discovery-synthesis and biological activity","volume":"100","author":"Nadar","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2026.118822_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113957","article-title":"Identification and validation of a novel dual small-molecule TLR2\/8 antagonist","volume":"177","author":"Grabowski","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118822_bib53","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1038\/s41467-024-53770-9","article-title":"Label-free biosensor assay decodes the dynamics of Toll-like receptor signaling","volume":"15","author":"Holze","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118822_bib54","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1021\/acs.jcim.4c02158","article-title":"OpenMMDL - simplifying the complex: building, simulating, and analyzing protein\u2013ligand systems in OpenMM","volume":"65","author":"Talagayev","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118822_bib55","doi-asserted-by":"crossref","first-page":"16375","DOI":"10.1074\/jbc.M116.735431","article-title":"Ligand binding ensembles determine graded agonist efficacies at a G protein-coupled receptor","volume":"291","author":"Bock","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413474","article-title":"Dynophore-based approach in virtual screening: a case of human DNA topoisomerase II\u03b1","volume":"22","author":"Jane\u017ei\u010d","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118822_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137983","article-title":"Synthesis, molecular modeling, DFT studies, and EPR analysis of 1,4-dihydropyridines as potential calcium channel blockers","volume":"1307","author":"Ko\u00e7ak Aslan","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.118822_bib58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/ph15060680","article-title":"In vitro, in vivo and in silico characterization of a novel kappa-opioid receptor antagonist","volume":"15","author":"Puls","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118822_bib59","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1021\/acsmedchemlett.4c00350","article-title":"From virtual screens to cellular target engagement: new small molecule ligands for the immune checkpoint LAG-3","volume":"15","author":"Fuchs","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118822_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2025.102932","article-title":"Heterocyclic compounds with diverse biological activities: a review of quinazoline and quinazolinone derivatives","volume":"19","author":"Kalakwade","year":"2026","journal-title":"Results Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ddtec.2018.04.004","article-title":"Automated assays for thermodynamic (equilibrium) solubility determination","volume":"27","author":"Sou","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2026.118822_bib62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2174\/138920008786485100","article-title":"In vitro solubility assays in drug discovery","volume":"9","author":"Kerns","year":"2008","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejmech.2026.118822_bib63","first-page":"21","article-title":"QSAR models for the prediction of plasma protein binding","volume":"3","author":"Ghafourian","year":"2013","journal-title":"Bioimpacts"},{"key":"10.1016\/j.ejmech.2026.118822_bib64","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1021\/acsmedchemlett.0c00264","article-title":"Discovery of potent and orally bioavailable small molecule antagonists of Toll-like receptors 7\/8\/9 (TLR7\/8\/9)","volume":"11","author":"Mussari","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118822_bib65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/prot.22234","article-title":"Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures","volume":"75","author":"Labute","year":"2009","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2026.118822_bib66","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118822_bib67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein\u2212ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118822_bib68","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/(SICI)1096-987X(199604)17:5\/6<490::AID-JCC1>3.0.CO;2-P","article-title":"Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94","volume":"17","author":"Halgren","year":"1996","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.118822_bib69","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.ejmech.2026.118822_bib70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.118822_bib71","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A"},{"key":"10.1016\/j.ejmech.2026.118822_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00268978400101201","article-title":"A molecular dynamics method for simulations in the canonical ensemble","volume":"52","author":"Nos\u00e9","year":"1984","journal-title":"Mol. Phys."},{"key":"10.1016\/j.ejmech.2026.118822_bib73","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/00268979600100761","article-title":"Explicit reversible integrators for extended systems dynamics","volume":"87","author":"Martyna","year":"1996","journal-title":"Mol. Phys."},{"key":"10.1016\/j.ejmech.2026.118822_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.ejmech.2026.118822_bib75","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2026.118822_bib76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:44:46Z","timestamp":1781271886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":76,"alternative-id":["S0223523426002679"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118822","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel pyrimidine and quinazoline-based small-molecule Toll-like receptor 8 antagonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118822"}}